AR047810A1 - Proceso quimico - Google Patents

Proceso quimico

Info

Publication number
AR047810A1
AR047810A1 ARP050100607A ARP050100607A AR047810A1 AR 047810 A1 AR047810 A1 AR 047810A1 AR P050100607 A ARP050100607 A AR P050100607A AR P050100607 A ARP050100607 A AR P050100607A AR 047810 A1 AR047810 A1 AR 047810A1
Authority
AR
Argentina
Prior art keywords
chemical process
processes
preparing compounds
formula group
chemical
Prior art date
Application number
ARP050100607A
Other languages
English (en)
Inventor
Margaret A Butlin
Roger Butlin
Philip J Hogan
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR047810A1 publication Critical patent/AR047810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Se describen procesos para preparar compuestos de grupo de formulas (1).
ARP050100607A 2004-02-20 2005-02-18 Proceso quimico AR047810A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process

Publications (1)

Publication Number Publication Date
AR047810A1 true AR047810A1 (es) 2006-02-22

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100607A AR047810A1 (es) 2004-02-20 2005-02-18 Proceso quimico

Country Status (32)

Country Link
US (2) US7626020B2 (es)
EP (3) EP2325189A3 (es)
JP (2) JP2007523906A (es)
KR (2) KR20120036998A (es)
CN (1) CN1922193B (es)
AR (1) AR047810A1 (es)
AT (1) ATE535532T1 (es)
AU (1) AU2005214138B2 (es)
BR (1) BRPI0507847A (es)
CA (1) CA2555554A1 (es)
CL (1) CL2011003138A1 (es)
CY (1) CY1112555T1 (es)
DK (1) DK2135873T3 (es)
ES (1) ES2375201T3 (es)
GB (1) GB0403744D0 (es)
HK (1) HK1139689A1 (es)
HR (1) HRP20120031T1 (es)
IL (2) IL177505A (es)
MY (1) MY142268A (es)
NO (1) NO20064012L (es)
PL (1) PL2135873T3 (es)
PT (1) PT2135873E (es)
RS (1) RS52300B (es)
RU (1) RU2386636C2 (es)
SA (1) SA05260017B1 (es)
SG (1) SG153856A1 (es)
SI (1) SI2135873T1 (es)
TW (1) TWI347947B (es)
UA (1) UA83418C2 (es)
UY (1) UY28754A1 (es)
WO (1) WO2005080403A2 (es)
ZA (1) ZA200606579B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
MX361011B (es) 2010-02-03 2018-11-26 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
ES2893100T3 (es) 2015-10-12 2022-02-08 Advanced Cell Diagnostics Inc Detección in situ de variantes de nucleótidos en muestras con un elevado nivel de ruido, y composiciones y métodos relacionados con ésta

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (es) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
BR9910025A (pt) 1998-04-29 2000-12-26 Pfizer Prod Inc Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietóxi)-4-quinazo linamina desidratado e monoidratado
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
DE60030764T2 (de) 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
US6774131B1 (en) 2000-02-16 2004-08-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
AU2001264570A1 (en) 2000-05-31 2001-12-11 Warner Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
PE20021032A1 (es) 2001-04-11 2002-11-12 Abbott Lab Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1411933A1 (en) * 2001-08-03 2004-04-28 SmithKline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
WO2003015820A1 (fr) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
BRPI0417838A (pt) 2003-12-20 2007-04-17 Merck Patent Gmbh derivados de tetrahidroquinolina substituìdos por 2-(hetero) arila
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
PT2135873E (pt) 2012-01-16
WO2005080403A2 (en) 2005-09-01
SA05260017B1 (ar) 2008-07-14
HRP20120031T1 (hr) 2012-02-29
WO2005080403A3 (en) 2005-11-24
US7626020B2 (en) 2009-12-01
UY28754A1 (es) 2005-09-30
PL2135873T3 (pl) 2012-03-30
IL177505A0 (en) 2006-12-10
HK1139689A1 (en) 2010-09-24
KR20120036998A (ko) 2012-04-18
AU2005214138B2 (en) 2009-02-12
UA83418C2 (uk) 2008-07-10
MY142268A (en) 2010-11-15
EP2135873A2 (en) 2009-12-23
EP1718655A2 (en) 2006-11-08
RU2386636C2 (ru) 2010-04-20
IL177505A (en) 2010-12-30
EP2135873A3 (en) 2010-03-24
EP2135873B1 (en) 2011-11-30
US20100094010A1 (en) 2010-04-15
RS52300B (en) 2012-12-31
NO20064012L (no) 2006-11-06
US20080161565A1 (en) 2008-07-03
ZA200606579B (en) 2008-01-30
CL2011003138A1 (es) 2012-06-22
SG153856A1 (en) 2009-07-29
CN1922193B (zh) 2012-12-26
KR101196111B1 (ko) 2012-10-30
AU2005214138A1 (en) 2005-09-01
CN1922193A (zh) 2007-02-28
KR20060129483A (ko) 2006-12-15
CY1112555T1 (el) 2016-02-10
DK2135873T3 (da) 2012-02-13
ES2375201T3 (es) 2012-02-27
ATE535532T1 (de) 2011-12-15
TWI347947B (en) 2011-09-01
TW200538451A (en) 2005-12-01
BRPI0507847A (pt) 2007-07-10
CA2555554A1 (en) 2005-09-01
EP2325189A3 (en) 2011-10-26
EP2325189A2 (en) 2011-05-25
JP2007523906A (ja) 2007-08-23
RU2006133455A (ru) 2008-03-27
GB0403744D0 (en) 2004-03-24
IL194709A (en) 2010-12-30
JP2012031174A (ja) 2012-02-16
SI2135873T1 (sl) 2012-03-30

Similar Documents

Publication Publication Date Title
AR047810A1 (es) Proceso quimico
ATE433447T1 (de) Pyrimiidinverbindungen
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
UY29612A1 (es) Compuestos quimicos ii
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
SE0401762D0 (sv) Novel compounds
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
HK1159614A1 (en) Caspase inhibitors and uses thereof
EA200870038A1 (ru) Способ получения аминов
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
SE0400850D0 (sv) Novel Compounds
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
DE60312029D1 (de) Verfahren zur herstellung c-7 substituierter 5-androstene
SE0403085D0 (sv) Novel componds
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
ATE465152T1 (de) Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten
SE0403086D0 (sv) Compounds
EA201001252A1 (ru) Способ получения производных 3,6-дигидро-1,3,5-триазина
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal